Calciphylaxis is a disabling and life-threatening complication that primarily affects patients who are dialysis dependent. Reports have grown in the literature of cases occurring in those who have advanced chronic kidney disease (pre-end-stage renal disease) or in the setting of transplantation. There are also a few reports of cases occurring in those without any form of chronic kidney disease but with primary hyperparathyroidism. This disease entity is characterized by calcification, intimal hypertrophy, and thrombosis of small vessels that result in necrotizing, nonhealing ulcers—many of which are life threatening. Although several strategies aimed at treating and preventing this affliction have been reported in the literature, the outcome for most patients with calciphylaxis remains quite poor. We describe a patient with comparatively early-stage-3 chronic kidney disease who developed calciphylaxis in the setting of both primary and secondary hyperparathyroidism. Predictably, after subtotal parathyroidectomy, her wounds did not completely heal and her biochemical markers of hyperparathyroidism did not completely normalize until her underlying secondary hyperparathyroidism was treated medically. It was only after initiating cinacalcet that the patient experienced complete wound healing and resolution of her calciphylaxis. It also supports other authors’ findings that cinacalcet may be an important adjunct in the treatment of calciphylaxis.

Keywords: calciphylaxis, chronic kidney disease, cinacalcet, parathyroidectomy

Case report
A 66-year-old Caucasian woman with a medical history significant for chronic kidney disease (CKD) stage 3, hypertension, and morbid obesity was followed regularly at our nephrology and hypertension clinic. She was being treated aggressively for her hypertension, proteinuria, hyperuricemia, and secondary hyperparathyroidism (SHPT). Her baseline creatinine fluctuated between 1.5 mg/dL and 2.0 mg/dL, and eGFR (6 variable Modification of Diet in Renal Disease) between 24 and 34 mL/min/1.73 m². Her home medications included paricalcitol, gemfibrozil, febuxostat, pantoprazole, furosemide, lisinopril, latanoprost ophthalmic, and ferrous sulfate. Our patient had never taken warfarin, vitamin D, or any oral phosphate binders. In 2009, her intact parathyroid hormone (PTH) levels were noted to be rising despite her receiving oral paricalcitol 1 mcg daily. The dose was eventually adjusted up to 2 mcg daily without controlling her PTH which climbed as high as 216 pg/mL. Her calcium levels climbed from 9.0 to 10.4 mg/dL but never higher. Her serum phosphorous levels ranged from 2.9 to 3.7 mg/dL before, during, and after subsequent treatment. Most importantly, the Ca²⁺ × PO₄⁻² solubility product was never greater than 33.7. In August 2010, she presented with painful eruptions and ulcerations along the medial aspects of her thighs.
and intertriginous spaces of the lower extremities, slightly more on her right side. Initially, our patient was concerned that it represented a drug-related exanthem in response to a newly initiated uric acid-lowering agent. Accordingly, she had tried to self-medicate using over-the-counter preparations without success. Eventually she sought medical attention.

On exam, the presence of violaceous ulcerations were identified along the aforementioned distributions, some of which had already begun to drain purulent material. She was prescribed oral doxycycline as well as Cleocin-T gel and cultures and biopsy were procured while at the dermatology clinic. The patient was not noted to have had any substantial changes in her weight. An extensive hypercoagulable workup was negative, as was the presence of antiphospholipid antibodies. Complement levels were normal but serum protein electrophoresis found elevation of acute phase reactants suggesting acute inflammation. Cultures were unrevealing, however, the biopsy from the right medial thigh lesion revealed dermal necrosis with severe neutrophilic inflammation of the local blood vessels. The biopsy was nonspecific as calcium deposition was not identified, but the clinical picture was strongly suggestive of calciphylaxis. A repeat biopsy was not obtained due to our fear of inciting another ulcerating lesion. Furthermore, it has been shown that dermatopathology is most often nonspecific and often needs to be repeated several times to see the typical microvascular calcifications associated with calciphylaxis. For this reason, our nephrology clinic generally does not recommend biopsy of these ulcers.

At this point she was sent for a three-phase technetium bone scan that was markedly abnormal on blood pool imaging (Figure 1). It demonstrated widespread hyperintensities in the soft tissue of her thighs bilaterally corresponding to the suspect lesions, once again more so on her right side. The use of this imaging modality in calciphylaxis has been reported numerous times and has been shown to be abnormal with soft tissue uptake in up to 97% of patients with calciphylaxis, whether ulcerating or not. As such, she was referred for a technetium sestamibi parathyroid scan, which was suspicious for a parathyroid adenoma on the lower pole of the left lobe of the thyroid. This scan was repeated and confirmed by our surgeon who then performed a subtotal parathyroidectomy the following day. Intraoperatively, an enlarged parathyroid gland was identified, corresponding to the abnormality seen on imaging. It was later confirmed to be a hyperplastic parathyroid adenoma by pathology.

In the weeks following surgery, the drainage from her wounds begun to wane, margins began to heal, and her PTH level fell to 136 pg/mL, though did not fall lower on serial follow-up. It was at this point that her primary hyperparathyroidism was considered to have been definitively been treated, but the patient’s “background” SHPT had not. We were reluctant to give her oral vitamin D, or vitamin D receptor antagonists; instead, she was given cinacalcet. Within 3 months, her PTH had fallen to 38 pg/mL and her wounds had entirely healed.

Administration of the cinacalcet was not associated with hypocalcemia or significant change to our patient’s $\text{Ca}^{2+} \times \text{PO}_{4}^{2-}$ solubility product, which was low to begin with.

**Discussion**
Calciphylaxis (often referred to as calcific uremic arteriolopathy) is a disabling, and potentially life-threatening complication that has been reported to affect as many as 4% of patients with end-stage renal disease. It has been observed to occur primarily in patients receiving maintenance hemodialysis and peritoneal dialysis. However, syndromes resembling calciphylaxis have been reported in individuals with pre-end-stage renal disease-staged CKD and even more rarely in those without any evidence of renal dysfunction but with inflammatory bowel disease, malignancy, trauma, and primary hyperparathyroidism.

This disease entity is characterized by calcification, intimal hypertrophy, and thrombosis of small vessels that slowly lead to tissue ischemia followed by infarction. Predominantly affecting subcutaneous tissue, this microvasculopathic
process leads to the formation of painful nodules or plaques, which are often described as erythematous or violaceous foci that later erupt as necrotizing, nonhealing ulcers. These lesions are typically distributed in highly vascular regions with thick overlying adipose tissue such as the breast, abdomen, and thighs, although acral and even visceral organ involvement has been reported.4 The formation of these ulcerating necrotic lesions portends a grim prognosis as they are often accompanied by severe infectious complications resulting in mortality rates that can exceed 60%.3,5

Several strategies aimed at treating and preventing this affliction in the nondialysis population have been reported in the literature. These include early parathyroidectomy,5,7 sodium thiosulfate,8,9 vitamin D analogs,9 bisphosphonates,10 cinacalcet,10,11 and hyperbaric oxygen.12 Unfortunately, none of these maneuvers have been shown to be universally beneficial and the outcome for most patients afflicted with calciphylaxis remains quite poor.

We describe a unique case of a patient with stage 3 CKD who presented with calciphylaxis when she developed primary hyperparathyroidism superimposed on background SHPT that was actively being treated with paricalcitol. She developed her lesions in the face of escalating dosages of the vitamin D analog despite normal Ca\(^{2+}\) × PO\(^{4-}\) solubility products. What is interesting in this case is that her wounds did not begin to heal until her parathyroid adenoma was surgically removed and did not completely heal until her PTH level was normalized with cinacalcet.

PTH disrupts calcium homeostasis. In primary disease this is demonstrated in a straightforward way as PTH is secreted in a constitutive fashion from the parathyroid cells without regard for ambient serum calcium levels, often driving the remaining parathyroid glands into dormancy in the process. Hypercalcemia and/or high Ca\(^{2+}\) × PO\(^{4-}\) solubility products subsequently develop. In secondary disease the pathway is more complex.

In CKD, the kidney has a decreased ability to generate 1,25-dihydroxycholecalciferol (calcitriol) from its precursor ergocalciferol via the kidney 25(OH) 1-α-hydroxylase enzyme. Phosphate retention gradually occurs and this, in conjunction with reduced calcitriol levels, results in reduced intestinal calcium absorption and decreased serum calcium levels. As the degree of CKD progresses, the cellular expression of vitamin D receptors and calcium-sensing receptors (CaSRs) decrease within the parathyroid cells. Furthermore, the CaSRs are less sensitized to ambient calcium levels.13,14 These circumstances eventually lead to an increase in PTH release and a resultant rise in calcium levels. In the long-term, this phenomenon is maladaptive as it leads to bone demineralization (renal osteodystrophy). In these scenarios, PTH is believed by some investigators to enhance coronary artery calcifications13 and lead to the aforementioned microvascular calcification, intimal hypertrophy, and thrombosis, which in turn leads to ischemia and subsequent calciphylactic ulcers.14 More recently, fibroblast growth factor 23 (FGF-23) has been established as an important player in the regulation of phosphate-vitamin D homeostasis. FGF-23 concentration increases in CKD and contributes to the development of SHPT. Elevations in FGF-23 expression lead to the downregulation of residual renal 25(OH) 1-α-hydroxylase enzyme activity. This unfortunately potentiates the previously mentioned deficiency of calcitriol production, resulting in enhanced PTH synthesis and subsequent parathyroid hyperplasia.15

In our patient, both pathways were operating concurrently. It also explains why she had an excellent initial response to a surgical intervention in the form of a subtotal parathyroidectomy. As the parathyroid adenoma was removed, her PTH levels fell. However, it was not until the calcimimetic agent cinacalcet was added that the PTH level normalized followed by complete wound healing. Calcimimetic agents activate the CaSRs, thereby potentiating the effects of ambient extracellular calcium on parathyroid cell function.16 This, in effect, reengages a negative feedback loop and suppresses PTH secretion. Calcimimetics also upregulate CaSR--and vitamin D-receptor expression and, in animal models, reduce parathyroid gland hypertrophy.19 In our patient, the use of cinacalcet allowed us to lower her secondary elevations in PTH without having to provide her with calcitriol or vitamin D analogs, which theoretically may have worsened her calciphylaxis.

In conclusion, calciphylaxis is a disabling and potentially life-threatening complication most often accompanying advanced degrees of renal insufficiency. A variety of interventions have been proposed to treat and/or prevent this morbid condition; unfortunately, the outcome for most patients afflicted with calciphylaxis remains poor. To the best of our knowledge, this case represents the first reported case of an individual with stage 3 CKD who developed calciphylaxis amidst mixed hyperparathyroidism (both primary and secondary) and was successfully treated with subtotal parathyroidectomy (for pathologically confirmed parathyroid adenoma) followed by cinacalcet (for background SHPT). We feel this case is extraordinary because of the patient’s development of calciphylaxis in spite of her relatively mild stage of CKD, as well as clinical response to specific therapy targeted at the pathophysiology of both primary and SHPT as detailed. Based on our experience in conjunction
with that reported by others, we feel that administration of calcimimetics should be considered as an important adjunct in the treatment of calciphylaxis.

Authors’ contributions
MB: direct patient care, article conception, literature search, case review and summary, drafting of the original article. AH: direct patient care, critical review. All authors read and approved the final manuscript.

Acknowledgments
Written consent was obtained from the patient for publication of this study. The authors would like to thank Dr Ruth Hanno for her critical review and interpretation of the dermatopathology slides and Dr George Pavlidakey for his excellent dermatologic care and advice.

Disclosure
The authors declare that they have no competing interests in this work.

References